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Novel implications of Lingo-1 and its signaling partners in
schizophrenia
F Fernandez-Enright1,2,4, JL Andrews1,2,4, KA Newell1,2, C Pantelis3 and XF Huang1,2
Myelination and neurite outgrowth both occur during brain development, and their disturbance has been previously been
implicated in the pathophysiology of schizophrenia. Leucine-rich repeat and immunoglobulin domain-containing protein (Lingo-1)
is a potent negative regulator of axonal myelination and neurite extension. As co-factors of Lingo-1 signaling (Nogo receptor (NgR),
With No Lysine (K) (WNK1) and Myelin transcription factor 1 (Myt1)) have been implicated in the genetics of schizophrenia, we
explored for the ﬁrst time the role of Lingo-1 signaling pathways in this disorder. Lingo-1 protein, together with its co-receptor and
co-factor proteins NgR, tumor necrosis factor (TNF) receptor orphan Y (TROY), p75, WNK1 and Myt1, have never been explored in
the pathogenesis of schizophrenia. We examined protein levels of Lingo-1, NgR, TROY, p75, WNK1, Myt1 and myelin basic protein
(MBP) (as a marker of myelination) within the post-mortem dorsolateral prefrontal cortex (DLPFC) (37 schizophrenia patients versus
37 matched controls) and hippocampus (Cornu Ammonis, CA1 and CA3) (20 schizophrenia patients versus 20 matched controls from
the same cohort). Both of these brain regions are highly disrupted in the schizophrenia pathophysiology. There were signiﬁcant
increases in Lingo-1 (Po0.001) and Myt1 (P= 0.023) and a reduction in NgR (Po0.001) in the DLPFC in schizophrenia subjects
compared with controls. There were also increases in both TROY (P= 0.001) and WNK1 (P= 0.011) in the CA1 of schizophrenia
subjects and, in contrast to the DLPFC, there was an increase in NgR (P= 0.006) in the CA3 of schizophrenia subjects compared with
controls. No signiﬁcant difference was reported for MBP levels (P>0.05) between the schizophrenia and control groups in the three
tested regions. This is the ﬁrst time that a study has shown altered Lingo-1 signaling in the schizophrenia brain. Our novel ﬁndings
may present a direct application for the use of a Lingo-1 antagonist to complement current and future schizophrenia therapies.
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INTRODUCTION
Schizophrenia is a severe neuropsychiatric disorder with an elusive
etiology, thought to result from abnormal brain development
during the ﬁrst 3 decades of life.1 Dysfunction of axonal
myelination has been a prominent hypothesis of schizophrenia
pathophysiology, supported by gene expression,2–4
histopathology5,6 and imaging studies.7–10 Interestingly, myelina-
tion peaks during late adolescence, coinciding with the onset of
schizophrenia,11 and involves associative cortical regions impli-
cated in the disorder, such as dorsolateral prefrontal cortex
(DLPFC) and superior temporal gyrus.12 In normal brain develop-
ment, oligodendrocytes are the cells responsible for forming
myelin around neurons. Leucine-rich repeat and immunoglobulin
domain-containing protein (Lingo-1), a transmembrane signal-
transducing molecule selectively expressed on oligodendrocytes
and neurons,13 has been reported to be a potent negative
regulator of oligodendrocyte differentiation, axonal integrity and
myelination.13,14 Its action notably involves the Nogo receptor
(NgR) as a part of a co-receptor complex. NgR binds with either
the p75 neurotrophin receptor or tumor necrosis factor (TNF)
receptor orphan Y (TROY).15–17 The resulting trimolecular receptor
complex Lingo-1/NgR/p75 or Lingo-1/NgR/TROY activates Ras
homolog gene family, member A (RhoA), initiating a cascade of
intracellular molecular events resulting in collapse of growth
cones, preventing further axonal growth and inhibiting
myelination.13,18 The existence of additional signaling co-factors
has been suggested based on the absence of p75 and TROY on
Lingo-1 containing neurons projecting to the spinal cord.19
Using the intracellular domain of Lingo-1 as bait, Zhang et.al.20
identiﬁed several candidates directly interacting with Lingo-1
including serine threonine kinase With No Lysine K (WNK1). Both
suppression and overexpression of WNK1 promotes neurite
extension and eliminates the inhibitory response to the Nogo
ligand in cortical neurons.20 In addition, expression of the WNK1
gene has been reported to be upregulated in the PFC of
schizophrenia sufferers,21 suggesting that it has a role in this
disorder. Myelin transcription factor 1 (Myt1), a postmitotic
neuronal speciﬁc zinc protein, and its highly conserved homolog,
Myt1-like (Myt1l), are two other well-characterized direct intracel-
lular binding partners of Lingo-1. Although disruption of the Myt1l
gene was reported in a Dutch schizophrenia population,22 little is
known about the implication of the Myt1 gene and protein in
schizophrenia.
1Centre for Translational Neuroscience, Illawarra Health and Medical Research Institute, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW,
Australia; 2Schizophrenia Research Institute, Darlinghurst, NSW, Australia and 3Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne and
Melbourne Health, Melbourne, VIC, Australia. Correspondence: Dr F Fernandez-Enright, Illawarra Health and Medical Research Institute, Faculty of Science, Medicine and
Health, University of Wollongong, Northﬁelds Avenue, Wollongong 2522, NSW, Australia.
E-mail: fernande@uow.edu.au
4These authors contributed equally to this work.
Received 25 July 2013; revised 4 November 2013; accepted 10 November 2013
Citation: Transl Psychiatry (2014) 4, e348; doi:10.1038/tp.2013.121
© 2014 Macmillan Publishers Limited All rights reserved 2158-3188/14
www.nature.com/tp
Functional genetic polymorphisms in the NgR gene previously
associated with schizophrenia have been reported to directly
affect interactions between NgR and its ligands or with its co-
receptors (p75, TROY and Lingo-1) in in vitro neuronal culture.23,24
Interestingly, NgR knockout mice are now an established animal
model for schizophrenia,24 linking downregulation or loss of NgR
with schizophrenia; however, it is still unknown how NgR is
involved in the pathophysiology of the disease.
Despite the implication of some of Lingo-1’s co-factors in
schizophrenia, no studies have speciﬁcally investigated a link
between Lingo-1 and schizophrenia, although numerous studies
have reported a dysfunctional proﬁle of myelination gene
expression in the post-mortem PFC and hippocampus in
schizophrenia sufferers.2,25 As Lingo-1 is a known myelination
inhibitor shown to inhibit oligodendrocyte differentiation and
myelination when overexpressed,26 studying Lingo-1 in schizo-
phrenia is a valid and innovative avenue of research. For the ﬁrst
time, we have examined Lingo-1 and its signaling partners in post-
mortem schizophrenia DLPFC and hippocampus (CA1 and CA3
regions), regions highly disrupted in schizophrenia.27–29
MATERIALS AND METHODS
Human brain tissue samples
Human DLPFC and hippocampus (CA1 and CA3) samples were obtained
from the New South Wales (NSW) Brain Bank Network. The sample cohort
consisted of 37 schizophrenia subjects (including 7 schizoaffective disorder
subjects) and 37 controls, matched for age at death, post-mortem interval
(PMI), brain pH and RNA integrity (Table 1). Owing to limited availability of
hippocampus tissue from this same cohort, 20 schizophrenia subjects from
this cohort and their matched controls were used (Table 1). There was no
signiﬁcant difference in subject demographics (age at death, PMI, brain pH
and RNA integrity) between DLPFC and hippocampus cohorts (P>0.05;
Table 1). Further details regarding demography and clinical factors of all
subjects pre- and post-mortem have been previously described30 and can
be found in Supplementary Information (Supplementary Table ST1).
Subjects with schizophrenia were diagnosed using Diagnostic and
Statistical Manual of Mental Disorders IV criteria. All subjects with
schizophrenia were prescribed antipsychotics at the time of death and a
lifetime chlorpromazine equivalent was calculated for each patient. Clinical
assessments, selection of schizophrenia cases and matched controls,
assessment of tissue quality and preparation of tissue homogenates were
all performed by the NSW Brain Bank Network and Schizophrenia Research
Laboratory.30 All studies were approved by and conducted according to
the guidelines of the Human Research Ethics Committees at the University
of Wollongong (HE 99/222) and the University of NSW (HREC 07261).
Human brain tissue preparation
Tissue from human DLPFC samples was obtained from the middle one-
third (rostro-caudally) of the middle frontal gyrus from coronal slabs
anterior to the genu of corpus callosum30 (corresponding to Brodmann
Area 46). Tissue samples from both CA1 and CA3 regions of the
hippocampus were obtained from the level of the lateral geniculate
nucleus. Tissue was homogenized gently in a homogenizing buffer (50mM
Tris, pH 7.5, 50% glycerol), and diluted 1:20 (by volume) by protease
inhibitor cocktail (Sigma, Australia). Protein concentrations were deter-
mined using a spectrophotometer. All samples were diluted to a
concentration of 2 μg μl− 1 and stored at −80 °C until required for
immunoblotting, as previously detailed.31
Immunoblotting
Relative levels of all proteins were determined by immunoblot analysis.
Proteins were resolved by SDS-polyacrylamide gel electrophoresis and
were transferred to polyvinylidene ﬂuoride membranes (Bio-Rad, Australia).
Membranes were probed with anti-Lingo-1 (1:500; ab23631, Abcam, UK),
anti-NgR (1:500; ab26291, Abcam), anti-p75 (1:500; ab8874, Abcam), anti-
TROY (1:200; ab12126, Abcam), anti-WNK1 (1:500; ab128858, Abcam), anti-
Myt1 (1:500; ab82844, Abcam), anti-myelin basic protein (MBP) (1:1000;
ab53294, Abcam) primary polyclonal or monoclonal antibodies. Visualiza-
tion and quantiﬁcation of immunoblot bands was performed using the Gel
Logic 2200 Pro (Carestream Molecular Imaging; Rochester, NY, USA). All
samples were run in duplicate or triplicate, with samples loaded in a
randomized order with a relatively even number of schizophrenia and
control samples per gel to minimize the effects of gel-to-gel variability on
the results. A pooled sample, combining aliquots from all 74 subjects, was
loaded onto each gel within the experiment to account for any gel-to-gel
variability (which was calculated to be between 9 and 13% (1.28 ± 0.11 to
0.38± 0.05), and all immunoblot bands were normalized to a β-actin
(1:5000; MAB1501, Millipore, Australia) same lane loading control. Mean β-
actin expression levels did not differ between schizophrenia and control
groups in either DLPFC (P>0.05) or hippocampal regions (P>0.05). Levels of
β-actin mRNA have been previously shown to be unaltered in this cohort.30
All experiments and quantiﬁcations were performed blind to diagnosis. A
more detailed immunoblot method can be found in Supplementary
Information.
Statistical analysis
Statistical analyses were performed using SPSS (version 19.0, SPSS,
Chicago, IL, USA). All data were normally distributed (K-S
0.317≤ P≤ 1.000). Outliers were identiﬁed (cases deemed to be more
than two standard deviations (s.d.) from their respective group mean) and
removed before statistical analyses. Analyses of schizophrenia compared
with control groups were performed and reported in groups, with the
outliers removed. As our schizophrenia group consisted of schizophrenia
and schizoaffective subjects, analyses comparing the groups were
performed both including the schizoaffective subjects and with the
schizoaffective subjects excluded. Multivariate analyses of variance
(MANOVA) were performed to determine whether there was a signiﬁcant
difference in protein levels between schizophrenia and control groups.
Pearson’s correlations were performed to determine the extent to which
continuous variables (age at death, brain pH, RNA integrity, PMI, freezer
storage time and brain weight) were associated with changes in protein
expression. In cases where signiﬁcant associations with independent
variables were found, multivariate analyses of covariance (MANCOVA) were
performed to account for continuous variables that can affect protein
expression in post-mortem brain studies.32 Categorical confounds such as
gender and brain hemisphere were analyzed by two-way MANOVA. Cause
of death (suicide versus natural death) was also considered as a
Table 1. Subject demographics from DLPFC and hippocampus brain cohorts for schizophrenia
Demographics Control subjects Schizophrenia subjects
DLPFC Hippocampus DLPFC Hippocampus
Age at death
(years)
51.1± 14.6 58.2± 12.6 51.3± 14.1 55.5± 13.5
Post-mortem
interval (hours)
24.8± 11.0 26.1± 12.8 28.8± 13.8 28.3± 10.1
Brain pH 6.7± 0.3 6.6± 0.3 6.6± 0.3 6.6± 0.3
RNA integrity 7.3± 0.6 7.2± 0.7 7.3± 0.6 7.2± 0.5
Gender 7 F, 30 M 2 F, 18 M 13 F, 24 M 9 F, 11 M
Abbreviations: DLPFC, dorsolateral prefrontal cortex; F, female; M, male. Data are expressed as mean± s.d.
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confounding factor and was analyzed within the schizophrenia group
using independent t-tests. Bonferroni correction for multiple testing set
the t-test signiﬁcance to Po0.007. The signiﬁcance for all other statistical
tests was set to Po0.05. Data are expressed as mean± s.d.
Note: The term ‘schizophrenia subjects’ hereafter refers to the whole
group including the schizoaffective subjects unless otherwise speciﬁed.
Diagnostic and Statistical Manual of Mental Disorders IV diagnosed
schizophrenia subjects will be referred to as ‘schizophrenia only’.
Figure 1. Relative protein expression in the (a) dorsolateral prefrontal cortex (DLPFC), (b) CA1 and (c) CA3 in control (blue circles) and
schizophrenia, including schizoaffective (red squares) subjects. *Po0.05, **Po0.01 and ***Po0.001.
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RESULTS
Protein expression in the DLPFC and hippocampus in
schizophrenia versus control subjects
Lingo-1. Analysis of the DLPFC showed a statistically signiﬁcant
12% increase in levels of Lingo-1 protein in schizophrenia subjects
compared with controls (F1,56 = 14.419; Po0.001; Figure 1a).
Following the removal of the schizoaffective subjects, this
difference increased to a 20% increase in Lingo-1 expression in
the schizophrenia-only group compared with controls
(F1,51 = 15.229; Po0.001; Supplementary Figure SF1A). In contrast,
hippocampal results showed no signiﬁcant difference in Lingo-1
expression between schizophrenia subjects and controls in neither
CA1 (F1,30 = 0.664; P= 0.422; Figure 1b) nor CA3 regions
(F1,29 = 0.066; P= 0.800; Figure 1c). Similarly, following the removal
of the schizoaffective subjects, there was no signiﬁcant difference
in Lingo-1 expression in the CA1 (F1,27 = 0.508; P= 0.482;
Supplementary Figure SF1B) nor CA3 (F1,26 = 0.063; P= 0.804;
Supplementary Figure SF1C).
NgR. In contrast to Lingo-1, NgR protein levels showed a
statistically signiﬁcant 16% reduction in schizophrenia subjects
compared with controls in the DLPFC (F1,56 = 27.229; Po0.001;
Figure 1a). When the schizoaffective subjects were removed, this
difference increased further to an 18% reduction in NgR
expression in the schizophrenia-only group compared with
controls (F1,51 = 26.277; Po0.001; Supplementary Figure SF1A).
There was no signiﬁcant change in NgR expression in the CA1
hippocampal region either including (F1,30 = 0.224; P= 0.639;
Figure 1b) or excluding the schizoaffective subjects (F1,27 = 0.218;
P= 0.644; Supplementary Figure SF1B). However, there was a
highly signiﬁcant 31.5% increase in NgR expression between
schizophrenia and control subjects (F1,29 = 8.900; P= 0.006;
Figure 1c) in the CA3. When schizoaffective subjects were
removed, a 25% increase was still observed in the
schizophrenia-only group compared with controls (F1,26 = 6.237;
P= 0.019; Supplementary Figure SF1C).
p75 and TROY. Interestingly, neither p75 nor its homolog TROY
showed any signiﬁcant difference in levels of protein expression in
schizophrenia subjects compared with controls in the DLPFC
either before (F1,56 = 2.012; P= 0.162 and F1,56 = 0.745; P= 0.392;
Figure 1a) or after the removal of the schizoaffective subjects
(F1,51 = 1.174; P= 0.284 and F1,51 = 1.135; P= 0.292; Supplementary
Figure SF1A). p75 remained unaltered in both CA1 and CA3
regions of the hippocampus when including (F1,30 = 2.481;
P= 0.126; Figure 1b and F1,29 = 1.166; P= 0.289; Figure 1c) and
excluding the schizoaffective subjects (F1,27 = 3.436; P= 0.075;
Supplementary Figure SF1B and F1,26 = 0.814; P= 0.375;
Supplementary Figure SF1C). However, its homolog TROY showed
a signiﬁcant 14.5% increase in the CA1 (F1,30 = 13.039; P= 0.001;
Figure 1b) in schizophrenia that was increased to an 18% increase
following the removal of the schizoaffective subjects
(F1,27 = 12.037; P= 0.002; Supplementary Figure SF1B). The level
of TROY expression remained unchanged in the CA3 region both
including (F1,29 = 0.080; P= 0.779; Figure 1c) and excluding the
schizoaffective subjects (F1,26 = 0.126; P= 0.726; Supplementary
Figure SF1C).
WNK1. Analysis of WNK1 revealed no statistically signiﬁcant
difference in expression in the DLPFC between schizophrenia and
control subjects (F1,56 = 0.172; P= 0.864; Figure 1a), nor when the
schizoaffective subjects were removed (F1,51 = 0.162; P= 0.689;
Supplementary Figure SF1A). However, a 25.5% increase in WNK1
expression was observed in the CA1 of schizophrenia subjects
compared with controls (F1,30 = 7.284; P= 0.011; Figure 1b) that
was increased to a signiﬁcant 30% increase in WNK1 expression
when the schizoaffective subjects were removed (F1,27 = 6.030;
P= 0.021; Supplementary Figure SF1B). No signiﬁcant alterations in
WNK1 expression were observed in the CA3 either before
(F1,29 = 1.223; P= 0.278; Figure 1c) or after the removal of the
schizoaffective subjects (F1,26 = 1.255; P= 0.273; Supplementary
Figure SF1C).
Myt1. Within the DLPFC, a signiﬁcant 11.5% increase in Myt1
expression was observed in schizophrenia compared with control
groups (F1,56 = 5.494; P= 0.023; Figure 1a). When the schizoaffec-
tive subjects were removed, this difference increased to a 14.5%
increase in Myt1 expression in the schizophrenia-only group
compared with controls (F1,51 = 5.041; P= 0.029; Supplementary
Figure SF1A). There were no signiﬁcant differences in Myt1
expression levels in either CA1 nor CA3 hippocampal regions
either before (F1,30 = 0.996; P= 0.326; Figure 1b and F1,29 = 0.036;
P= 0.852; Figure 1c) or after the removal of the schizoaffective
subjects (F1,27 = 0.528; P= 0.474; Supplementary Figure SF1B and
F1,26 = 0.025; P= 0.875; Supplementary Figure SF1C).
MBP. MBP levels in the DLPFC revealed no signiﬁcant alteration
between the schizophrenia and control groups (F1,56 = 0.001;
P= 0.980; Figure 1a), nor was there any change following the
removal of the schizoaffective subjects (F1,51 = 0.021; P= 0.886;
Supplementary Figure SF1A). Analysis of hippocampal regions
showed no signiﬁcant alterations in MBP expression in either CA1
(F1,30 = 1.043; P= 0.315; Figure 1b) or CA3 regions (F1,29 = 0.006;
P= 0.940; Figure 1c). Similarly, there was no change in either the
CA1 (F1,27 = 0.592; P= 0.448; Supplementary Figure SF1B) nor in
the CA3 (F1,26 = 0.068; P= 0.796; Supplementary Figure SF1C)
following the exclusion of the schizoaffective subjects.
Confounding factors had no impact on levels of protein
expression
Peri-mortem and demographic variables can im pact on protein
expression in post-mortem human studies.32 A number of
continuous variables were found to be signiﬁcantly correlated
with levels of protein expression in our study (Supplementary
Tables ST2-ST4). MANCOVAs were conducted to account for those
continuous variables (age at death, brain pH, PMI, freezer storage
time and brain weight) that did correlate with levels of protein
expression, which might have an impact on our data. Importantly,
when MANCOVAs were conducted, the signiﬁcant difference in
protein expression between schizophrenia and control subjects
was retained within Lingo-1 data (F1,50 = 10.376; P= 0.002), NgR
data (F1,50 = 29.250; Po0.001) and Myt1 data (F1,50 = 8.612;
P= 0.005) in the DLPFC. Signiﬁcance was also retained in TROY
data (F1,24 = 12.329; P= 0.002) and WNK1 data (F1,24 = 10.333;
P= 0.004) in the CA1, as well as in NgR data (F1,23 = 7.250;
P= 0.013) in the CA3. All nonsigniﬁcant data for remaining
proteins in their respective brain regions remained nonsigniﬁcant
following the MANCOVAs (P>0.05).
Gender was ana lyzed as a categorical confound by two-way
MANOVA. It was revealed that there was a signiﬁcant diagnosis by
gender interaction for Lingo-1 levels in the DLPFC (F1,55 = 4.362;
P= 0.041). A statistically signiﬁcant 19.5% increase in Lingo-1
expression was found in schizophrenia males compared with
control males (Po0.001). There was no signiﬁcant diagnosis by
gender interaction for Lingo-1 either within the CA1 (F1,28 = 1.543;
P= 0.225) or CA3 (F1,27 = 4.119; P= 0.052) hippocampal regions. In
addition, there were no signiﬁcant diagnosis by gender interac-
tions within the DLPFC, CA1 or CA3 for any of the remaining
proteins (Supplementary Table ST5). Brain hemisphere was also
analyzed as a categorical confound by two-way MANOVA. There
were no signiﬁcant diagnosis by hemisphere interactions for any
of the tested proteins in any of the tested brain regions
(Supplementary Table ST5).
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Finally, we assessed whether our proteins of interest varied with
incidence of suicide compared with natural death among our
schizophrenia subjects. Independent t-tests revealed that there
was a slight decrease in Lingo-1 expression in the DLPFC of
schizophrenia subjects who committed suicide compared with the
schizophrenia subjects who died of natural causes (t1,26.440 =
−2.159; P= 0.040). In contrast, there was an increase in both NgR
(t1,35 = 2.471; P= 0.018) and Myt1 (t1,10.900 = 2.577; P= 0.026)
expression in the DLPFC of schizophrenia subjects who committed
suicide compared with those who died of natural causes.
However, Bonferroni correction for multiple testing resulted in a
signiﬁcance level of Po0.007; therefore, all signiﬁcance related to
the incidence of suicide was lost. All other proteins in all brain
regions were found to have no signiﬁcance relating to the
incidence of suicide in the schizophrenia subjects.
DISCUSSION
This is the ﬁrst study to examine the expression proﬁle of Lingo-1
and its signaling partner proteins in schizophrenia, identifying
alterations of these pathways in the DLPFC and hippocampus
(CA1 and CA3)—brain regions highly relevant to schizophrenia
pathophysiology providing highly sought after, novel directions
for therapeutic strategies.
First evidence for the implication of Lingo-1 in schizophrenia
Neuronal sprouting and myelination are developmental mile-
stones shown to be disrupted in schizophrenia and are an integral
part of the neurodevelopmental hypothesis for schizophrenia.33–35
Accordingly, Lingo-1 has been shown to be expressed early in
embryonic development (E14 in rodents) in both oligodendro-
cytes and neurons,36 and has been shown to inhibit axonal
outgrowth and myelination in the brain.13,37 These signiﬁcant
parallels between Lingo-1 and neural development support the
idea that Lingo-1 may be a contributing factor to schizophrenia
pathogenesis, but will require additional studies to elucidate this
role. Our study reports, for the ﬁrst time, levels of Lingo-1 protein
expression in post-mortem DLPFC, CA1 and CA3 in schizophrenia.
A signiﬁcantly higher level of Lingo-1 protein was found in the
DLPFC from schizophrenia compared with control subjects
(Po0.001) but not in the hippocampus (P>0.05). Downregulation
of epidermal growth factor (EGF) receptor (EGFR) induced by
Lingo-1’s inhibitory action may be partly involved in the regional
speciﬁcity of Lingo-1 expression in DLPFC compared with
hippocampus in schizophrenia brains. Lingo-1 can directly inhibit
EGFR independently of EGF activation (Figure 2a), leading to
inhibition of PI3/Akt signaling pathways.38,39 Owing to limited
quantities of post-mortem tissue available from this schizophrenia
brain cohort, it was not possible to measure levels of EGFR in
DLPFC and hippocampus of this cohort. However, previous post-
mortem studies have reported higher levels of EGFR protein in
DLPFC (Brodmann area 46) but not hippocampal regions in
schizophrenia versus control brains.40 Although it is unclear how
Lingo-1 inhibits EGFR expression and function, higher levels of
Lingo-1 observed only in DLPFC and not in hippocampus of
schizophrenia brains in our study seem pertinent. In the context
of schizophrenia pathophysiology, we postulate that greater levels
of EGFR in the DLPFC may have a role in Lingo-1 upregulation
observed in this region, leading to inhibition of PI3/Akt signaling
pathways in schizophrenia (Figure 2b).
Similar to the expression proﬁle of Lingo-1, we found a
signiﬁcantly higher level of Myt1 protein in the DLPFC
(P= 0.023) of schizophrenia compared with control subjects, but
similar to Lingo-1, levels of Myt1 were not signiﬁcantly altered in
CA1 or CA3 (P>0.05). As Lingo-1 is also upregulated in the DLPFC
in the schizophrenia group, it can be considered that inhibition of
Akt signaling pathways by Lingo-1 through its different signaling
partners (Figure 2b) may reduce negative regulation of Myt1 by
Akt intracellularly, resulting in higher levels of Myt1 in this region.
Considering the role of Lingo-1 and Myt1 in oligodendrocyte and
myelin dysfunction, it was not surprising to ﬁnd an increase in
levels of both these proteins in the DLPFC. Although these
changes may be associated with alterations in oligodendrocyte
and myelin function, we did not observe any changes in MBP
levels, as an indication of myelination, between groups. A
reduction in MBP expression was previously reported by a smaller
study in the enthorhinal cortex between schizophrenia and
control groups;41 however, it is difﬁcult to compare MBP
expression between studies, as many factors can inﬂuence
myelination analysis such as age at death, cause of death between
cohorts and antipsychotic treatment (Supplementary Table ST4).42
Further, post-mortem and imaging studies are required to address
the question of how the differential Lingo-1 expression proﬁle
may affect myelination processes in schizophrenia brains.
Regulation of Lingo-1 pathways in schizophrenia: brain structure-
speciﬁc relationship?
Unlike Lingo-1 expression, our study found NgR expression levels
to be decreased in the DLPFC of schizophrenia compared with
control subjects (Po0.001). This ﬁnding in schizophrenia subjects
is supported by an animal study, suggesting that NgR and Lingo-1
may be functionally coupled, following a demonstration of inverse
regulation of NgR and Lingo-1 mRNA expression in the cortex as a
result of drug-induced brain activity.43 However, we reported no
change in NgR levels in CA1 (P>0.05), whereas a signiﬁcantly
higher level of NgR expression was found in CA3 (P= 0.006) from
schizophrenia compared with control subjects. These ﬁndings
highlight brain structure-speciﬁc regulation of NgR in schizo-
phrenia; however, it remains unclear how these opposing NgR
changes contribute to schizophrenia pathophysiology.
We observed a signiﬁcant increase in levels of WNK1 in CA1
from schizophrenia compared with control subjects (P= 0.011),
but not in DLPFC or CA3 (P>0.05). As illustrated in Figure 2a and as
reported previously,20 overexpression of WNK1 reduces Nogo-
induced inhibition of neurite extension, and thus inhibits
activation of RhoA.20 Considering the higher level of WNK1 that
is present in the CA1 and not in the CA3 of schizophrenia
compared with control subjects, together with the inhibitory
potential on NgR by WNK1, we speculate that WNK1 may
normalize CA1 levels of NgR resulting in a similar level of NgR
expression in this brain region in schizophrenia compared with
controls (Figure 2c). Further investigations are necessary to deﬁne
how this process occurs in vivo. To our knowledge, NgR protein
expression levels in post-mortem tissue have only ever been
reported in hippocampus in a cohort for Alzheimer’s Disease,44
where increased NgR expression was found in Alzheimer’s
patients, suggesting a common role of NgR in a larger scope of
brain disorders.
With regard to schizophrenia, few studies have reported levels
of expression of p75 in the post-mortem schizophrenia brain,
despite brain-derived neurotrophic factor (another widely dis-
tributed central nervous system neurotrophin) levels being
extensively studied in schizophrenia in serum and post-mortem
brains owing to its key regulatory role in synaptic plasticity and
neuronal a ctivity.45 Similar to our results in the hippocampus and
DLPFC, Dunham et. al.46 reported no change in p75 in the
hippocampus of their schizophrenia group compared with
controls in the Stanley consortium brains. Given that expression
of p75 is higher in the developing brain compared with the adult
brain, where its expression is limited to certain neuronal
subpopulations,17 examination of TROY (functional homolog of
p75 in the Lingo-1/NgR complex; Figure 2a) levels in the central
nervous system was pertinent in the context of this study. No
difference in expression of TROY was found in the DLPFC or in the
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CA3 from the schizophrenia group compared with controls
(P>0.05); however, a signiﬁcantly higher level of TROY was
observed in the CA1 of schizophrenia patients compared with
controls (P= 0.001). As TROY is a major partner of Lingo-1/NgR/
TROY complex, responsible for downstream cellular transduction,
and considering the upregulation of NgR we have reported in the
CA3, we can ask if there was a causal relationship between our
hippocampal results. However, TROY levels were not signiﬁcantly
different in the CA3, suggesting additional mechanisms may be
involved in the regulation of this protein that will need to be
further investigated.
Similar to TROY, WNK1 (a negative regulator of NgR) was found
to be elevated in schizophrenia compared with control brains
within CA1 (P= 0.011) but not CA3 or DLPFC (P>0.05). This last
result observed in our study was in accordance with literature
reporting a similar level of WNK1 gene expression in DLPFC post-
mortem tissue from schizophrenia sufferers compared with
controls.21 However, it is unclear why WNK1 is overexpressed
only in the CA1 region in our schizophrenia group. Interestingly,
overexpression of WNK1 has also been reported to signiﬁcantly
reduce the interaction between endogenous WNK1 and Lingo-1,
suggesting that it may serve as a binding platform for Lingo-1,
however, its kinase activity may not be necessary for Lingo-1
signaling.20 Furthermore, disruption of the WNK1 gene in mice
leads to death of the embryo at day 13,47,48 suggesting an
essential role of WNK1 in embryonic and neural development,
which is a critical period implicated in schizophrenia.
A structure-speciﬁc regulation for Lingo-1 pathways seems to
apply in the context of schizophrenia pathophysiology (Figure 2).
Interestingly, differences in the myelination proﬁle of DLPFC and
hippocampus have been reported, showing an abundance of
myelination in early development in the hippocampus, whereas
levels were reported to be low at birth in the PFC, increasing
throughout different stages of life.1,49 This differential and
regionally speciﬁc myelination proﬁle throughout development
might support a brain region-speciﬁc regulation of the various
pathways involved in myelination processes throughout life.
Our results show alterations in Lingo-1 signaling pathways in
both the schizophrenia-only group and the entire schizophrenia
group including schizoaffective subjects compared with controls.
This suggests that the variations in these pathways are applicable
to the schizophrenia spectrum. Nevertheless, as the magnitude of
change in our results were generally increased in the
schizophrenia-only group compared with controls, it seems that
the changes in Lingo-1 signaling pathways reported in this study
may be more speciﬁc to schizophrenia than schizoaffective
disorder. Interestingly, a study that examined myelination genes
in the Stanley consortium brains (15 schizophrenia and 15 bipolar
disorder patients compared with controls) showed that both
diagnostic groups had a differential expression proﬁle of
myelination-related genes compared with controls. The differen-
tial expression proﬁle of the genes was not the same across
schizophrenia and bipolar disorder subjects; however, there was a
signiﬁcant overlap.3 As schizoaffective disorder is characterized by
Figure 2. Schematization of Lingo-1signaling pathways in the (a) healthy brain, (b) dorsolateral prefrontal cortex (DLPFC) region from
schizophrenia sufferers and (c) hippocampus region from schizophrenia sufferers. Akt, protein kinase B (PKB); EGF, epidermal growth factor;
EGFR, epidermal growth factor receptor; ERK, extracellular signal-reduced kinase; Lingo-1, leucine-rich repeat and immunoglobulin domain-
containing protein; MEK, mitogen-activated protein kinase; NGF, nerve growth factor; NgR, Nogo receptor; P75, P75 neurotrophin receptor;
PI3-K, phosphatidylinositide 3-kinase; RhoA, Ras homolog gene family, member A; TrkA, transforming tyrosine kinase protein receptor A; TROY
(TNFRSF19), tumor necrosis factor receptor super family, member 19; WNK1, With No Lysine (K).
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both the psychotic symptoms of schizophrenia and the mood
swing symptoms of bipolar disorder, it seems likely that
myelination disturbances related to Lingo-1 pathways are more
speciﬁc to schizophrenia subjects only. However, further investi-
gations are necessary using a cohort that includes a wider number
of schizoaffective patients compared with schizophrenia and
controls to conﬁrm this hypothesis.
The limitations of this study brought about by the utilization of
post-mortem brain tissues have to be considered. As reported in
the results section and in Supplementary Tables ST2-ST4,
expression levels of the tested proteins remain signiﬁcant after
accounting for confounding factors from our brain cohort
demographics. Both age at death (r= -0.397; P= 0.015) and
duration of illness (r= -0.377; P= 0.021) were signiﬁcantly corre-
lated with NgR protein expression in the DLPFC of schizophrenia
subjects, suggesting an age-related effect on NgR protein levels in
schizophrenia. It has previously been shown that age at death is
inextricably linked to duration of illness in this schizophrenia brain
cohort.30 The longer a patient lives with schizophrenia, the longer
time frame they have to accumulate detrimental neural changes,
thus it cannot be determined whether NgR protein levels are
correlated with age at death or the length of time they lived with
the disorder.
We can see from the correlations shown by our study that the
longer the duration of illness, or the older the patients were, the
lower the NgR levels in the DLPFC. Interestingly, EGF levels have
been previously reported to be positively correlated with duration
of illness in the same brain region within another post-mortem
schizophrenia cohort.40 As EGF levels activate WNK1, (Figure 2a),
and considering the elevated EGF levels in long-term schizo-
phrenia, a downregulation of NgR according to duration of illness
seems consistent within the context of our results and hypothesis.
Furthermore, a positive correlation between WNK1 levels and
antipsychotic treatment was also shown in the CA1 hippocampal
region within the schizophrenia group (r= 0.466; P= 0.039). As
reported by previous primate, rodent and cell line studies,
antipsychotic treatment (notably second generation antipsycho-
tics) can induce modiﬁcations in major intracellular cascades (such
as extracellular signal-reduced kinase and Akt signaling pathways)
leading to changes in neuronal plasticity and survival.49 As the
majority of schizophrenia patients in our study were treated with
second generation antipsychotic drugs (Supplementary Table ST1)
and because of the suggested activation of WNK1 by Akt signaling
pathways (Figure 2a), it appears that the signiﬁcant difference in
WNK1 levels reported in the CA1 of schizophrenia patients
compared with controls might be inﬂuenced by psychotropic
treatment. However, the majority of reports studying molecular
mechanisms of neuroprotective effects of antipsychotic drugs
were performed in the PFC, where we did not report any
signiﬁcant alterations in WNK1 levels in schizophrenia compared
with control groups.
In summary, we provide the ﬁrst report investigating the
implication of Lingo-1 and its signaling partner proteins in
schizophrenia pathophysiology. We show for the ﬁrst time a brain
structure-speciﬁc alteration of Lingo-1 signaling pathways in
schizophrenia with: (1) signiﬁcantly elevated levels of Lingo-1
and Myt1 proteins, and a decreased level of NgR protein in the
DLPFC; (2) a signiﬁcant increase of downstream Lingo-1 co-factors
TROY and WNK1 in the CA1; and (3) signiﬁcantly elevated levels of
the Lingo-1 co-receptor NgR in the CA3. As illustrated in Figure 2
in the context of schizophrenia pathophysiology, two groups of
Lingo-1 pathways appear to have predominant brain-speciﬁc
roles: EGFR/Lingo-1/Myt1 in the PFC and WNK/NgR/TROY in the
hippocampus. Even if some of these signaling partners have been
previously involved in schizophrenia at the protein level (EGFR40
and Akt50) or genetic level (NgR23,24 WNK121 and Myt1l22 genes),
the integration of these protein synergies in the context of
schizophrenia is completely novel. However, further analysis will
be required to characterize these interactions at a molecular- and
cell-speciﬁc level (neurons versus oligodendrocytes). Nevertheless,
the relevance of our ﬁnding immediately offers a direct
application to schizophrenia therapy. Owing to the role of the
many Lingo-1 pathways as a negative regulator of myelination
and neurite outgrowth, and considering the implication of both of
these central processes in cognitive performance, antagonists of
Lingo-1 appear to be a new potential candidate in schizophrenia
therapy. We suspect that pharmacological blockade of Lingo-1 will
notably improve treatment for cognitive symptoms of schizo-
phrenia, which are currently not appropriately treated with
antipsychotic medications available at present. We are currently
exploring this hypothesis by investigating the potential for an
anti-Lingo-1 drug (one of which is being currently evaluated in
clinical trials for multiple sclerosis) in the treatment of schizo-
phrenia. By characterizing novel molecular mechanisms impli-
cated in schizophrenia, our results offer a new avenue of research
into the pathophysiology of schizophrenia and may facilitate
improvements to current therapies for treating this devastating
disease.
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